Uma Oils Warned – Medical Claims

The US Food and Drug Administration, or FDA, has made public its official warning letter to Shrankhla Upadhyay and her company, Vedame Oils, which does business as UMA Oils.

Unlike other warning letters we’ve seen from the FDA, this one apparently was not prompted by a physical inspection of Upadhyay’s facility. Rather, the letter focuses solely on claims made on the website. Four products in particular put Upadhyay in the FDA’s crosshairs:

  • Deep Nourish Extreme Dryness Treatment
  • Total Rejuvenation Night Face Oil
  • Deeply Clarifying Face Mask
  • Deep Clarifying Blemish Spot Treatment

Deep Nourish Extreme Dryness Treatment

Upadhyay peddled her dry skin “treatment” with promises like:

  • “powerful enough to combat eczema”
  • “relieves inflammation”
  • “combats bacteria”

Total Rejuvenation Night Face Oil

An overnight facial oil was touted for:

  • “diminished scars”
  • “powerful anti-inflammatory”
  • “anti-bacterial agents”

Deeply Clarifying Face Mask

A facial mask made claims like:

  • “antibacterial”
  • “fade acne scarring
  • “minimize inflammation”

Deep Clarifying Blemish Spot Treatment

An acne spot treatment got in on the act, promising:

  • “reduce pain”
  • “accelerate healing”
  • “very effective at every stage”

The FDA, naturally, counters with the fact that UMA Oils’ products have never been deemed safe or effective for any skin condition and, therefore, will be treated as new drugs that were illegally dumped onto the market.

As is typical with such warnings, Shrankhla Upadhyay and UMA Oils have been given 15 working days to remove the claims and respond. The FDA’s warning letter to UMA Oils was dated July 18, 2017.

UMA Oils pulls some marketing spiel after getting an FDA warning letter.

Bing-archived screenshot of UMA Oils website with an FDA-warned claim highlighted. As of August 1, 2017, the website appears to have been stripped of the alleged violating claims.


We’re ad-free. Help us stay that way with a 99-cent purchase for your Kindle, Nook or Kobo. Or share our work:

Categories: News